Companies · Biotechnology

MedVector Corp

El Segundo · Biotechnology

Diligence memoA one-page analyst read on MedVector Corp — recommendation, valuation, rhythm, risks.
$2.1M
Total raised · real
3
Rounds
1.4×
Latest step-up
Top 72%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Tue Oct 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

MedVector Corp looks over-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.15× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (78 peers) — value vs value, same stage and era.
  • Issuer reports no revenue, yet is modeled well above niche peers.
Active
  • Last raise 9 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

MedVector Corp is one of 4291 Biotechnology companies tracked from El Segundo. By capital raised it ranks in the long tail (ahead of 29% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
1
Investors (latest)
2025-10-07
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5M$5.0M$7.5M$10MPre-Seed · 2021-11-18 Raised $425K (real) Modeled valuation $9.9M (est)$425K$9.9MPre-Seed2021Pre-Seed · 2023-08-23 Raised $700K (real) Modeled valuation $5.5M (est)$700K$5.5MPre-Seed2023Pre-Seed · 2025-10-07 Raised $1.0M (real) Modeled valuation $2.1M (est)$1.0M$2.1MPre-Seed2025+$700K+$1.0MCumulative $2.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$425K · 2021
Pre-Seed extension$700K · 2023
Pre-Seed extension$1.0M · 2025

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$2.1M
Base estimate est.
$533K
Conservative case
$4.8M
Upside case
$5.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $9.9M · 2021-11-182021Pre-Seed · modeled $5.5M · 2023-08-23Pre-Seed · modeled $2.1M · 2025-10-072025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
0.7 yr
Elapsed time used
0.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
23 mo
Avg between rounds
$547K/yr
Capital velocity
4.6 yr
On record since
2021
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.1M
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 2.4× above median
This company$1.0M
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$2.1M
Sector median$64.2M

Raised more than 29% of sector peers (real $). Modeled value above 5% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #11 of 78.

This companyCohort peer
$1.0M$10.0M$100K$1.0M$10.0MCapital raised (log)Illexcor Holdings, LLC · Pre-Seed Raised $1.0M · modeled $3.0M (est)Reprogram Biosciences, Inc. · Pre-Seed Raised $1.0M · modeled $2.7M (est)Maxymune Therapeutics, Inc. · Pre-Seed Raised $850K · modeled $2.7M (est)EnZeta Immunotherapies, Inc. · Pre-Seed Raised $840K · modeled $2.6M (est)Eliaz Therapeutics Inc. · Pre-Seed Raised $850K · modeled $2.5M (est)Mekiri Bio, Inc. · Pre-Seed Raised $1.0M · modeled $2.3M (est)Cellerate Technologies, LLC · Pre-Seed Raised $1.0M · modeled $2.2M (est)Tinos Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $2.2M (est)Factor Bioscience LLC · Pre-Seed Raised $1.0M · modeled $2.2M (est)Toby, Inc. · Pre-Seed Raised $1.4M · modeled $2.1M (est)Real Health International Wellness Corp. · Pre-Seed Raised $1.0M · modeled $2.0M (est)MedVector Corp (this company) Raised $2.1M · modeled $2.1M (est)MedVector Corp
CompanyStageRaised · realValue · estvs peer med.
Illexcor Holdings, LLCPre-Seed$1.0M$3.0M3.08×
Reprogram Biosciences, Inc.Pre-Seed$1.0M$2.7M2.77×
Maxymune Therapeutics, Inc.Pre-Seed$850K$2.7M2.73×
EnZeta Immunotherapies, Inc.Pre-Seed$840K$2.6M2.67×
Eliaz Therapeutics Inc.Pre-Seed$850K$2.5M2.53×
Mekiri Bio, Inc.Pre-Seed$1.0M$2.3M2.31×
Cellerate Technologies, LLCPre-Seed$1.0M$2.2M2.29×
Tinos Therapeutics, Inc.Pre-Seed$1.0M$2.2M2.27×
Factor Bioscience LLCPre-Seed$1.0M$2.2M2.23×
Toby, Inc.Pre-Seed$1.4M$2.1M2.18×
MedVector Corp this companyPre-Seed$2.1M$2.1M2.15×
Real Health International Wellness Corp.Pre-Seed$1.0M$2.0M2.07×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$425K2021-11-18$2.4M$9.9M90%
Pre-Seed$700K2023-08-23$3.9M$5.5M90%
Pre-Seed$1.0M2025-10-07$5.6M$2.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$425K2021-11-18
    • First recorded raise — entered as Pre-Seed.
    • 6 investors on this round.
  2. Pre-Seed$700K2023-08-23
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • 7 investors on this round.
  3. Pre-Seed$1.0M2025-10-07
    • Raised again after 25 mo — slower than the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2027 ~Q3
Modeled next raise · ~23mo cadence
$1.4M
Modeled next size est.range $1.0M$2.3M
1.4×
Last step-up
$547K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Craig Lipset1 other2021-11
Scott Stout1 other2021-11
Dennis Patterson2021-11
Ian Leaman2021-11
Ted Barduson2021-11
Registry & provenance

MedVector Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1820902
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Jupiter Biomedical Research, Inc.BiotechnologyPre-Seed$2.1M$843Ksame sector · same stage
NovAb, Inc.BiotechnologyPre-Seed$2.0M$495Ksame sector · same stage
Zeo ScientifiX, Inc.BiotechnologyPre-Seed$1.9M$957Ksame sector · same stage
Inmedix, Inc.BiotechnologyPre-Seed$1.8M$343Ksame sector · same stage
Temple Therapeutics Holdings LtdBiotechnologyPre-Seed$1.7M$1.4Msame sector · same stage
Neopenda, PBCBiotechnologyPre-Seed$1.7M$730Ksame sector · same stage
Cleanbox Technology Inc.ManufacturingPre-Seed$2.1M$2.3Mnetwork1 shared operator · same stage
Cybele Microbiome, Inc.BiotechnologyPre-Seed$1.6M$1.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Medicovestor, Inc.BiotechnologySeed$7.3M90%
Viveve Medical, Inc.BiotechnologySeries A$12.3M88%
Vivex Biomedical, Inc.BiotechnologySeries A$227.0M85%
Cynvec LLCBiotechnologySeries A$542.3M85%
ReCor Medical, Inc.BiotechnologySeries B$873.2M85%
Medcura, Inc.BiotechnologySeries B$144.9M85%
Recros Medica, Inc.BiotechnologySeries A$149.0M85%
SiVEC Biotechnologies, Inc.BiotechnologySeed$8.4M85%
Frequently asked
How much funding has MedVector Corp raised?
MedVector Corp has raised approximately $2.1M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is MedVector Corp's estimated valuation?
Provath's modeled valuation for MedVector Corp is approximately $2.1M (modeled range $533K–$4.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is MedVector Corp at?
MedVector Corp's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Tue Oct 07.
What does MedVector Corp do and where is it based?
MedVector Corp operates in the Biotechnology sector, based in El Segundo.
Explore related

See where MedVector Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at MedVector Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.